CK Life Sciences Int'l., (Holdings) Inc. (HKG:0775)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
0.6600
-0.0100 (-1.49%)
At close: Mar 27, 2026
Market Cap6.34B +33.3%
Revenue (ttm)5.41B -2.0%
Net Income-186.81M
EPS-0.02
Shares Out9.61B
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,958,771
Average Volume6,760,627
Open0.6700
Previous Close0.6700
Day's Range0.6600 - 0.6700
52-Week Range0.4500 - 1.1000
Beta0.21
RSI21.15
Earnings DateMar 17, 2026

About HKG:0775

CK Life Sciences Int'l., (Holdings) Inc., an investment holding company, researches, develops, manufactures, commercializes, and sells health and agriculture-related products in the Asia Pacific and North America. It manufactures and markets plant protection products and soluble fertilizers; manufactures, blends, distributes, and sells fertilizers, pesticides, and related agricultural products; manufactures and distributes horticultural products for the home gardening market; and produces non-sterile prescription and over-the-counter medicines.... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1999
Employees 1,920
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 0775
Full Company Profile

Financial Performance

In 2025, HKG:0775's revenue was 5.41 billion, a decrease of -2.04% compared to the previous year's 5.52 billion. Losses were -186.81 million, 47.6% more than in 2024.

Financial Statements

News

CK Life unit merges with TransCode as Li Ka-shing firm eyes anticancer drugs

CK Life Sciences International is set to merge its subsidiary Polynoma with Nasdaq-listed TransCode Therapeutics, in a move expected to boost the pipeline of anticancer drugs, according to the biotech...

6 months ago - South China Morning Post

TransCode Acquires Polynoma From CK Life Sciences

(RTTNews) - TransCode Therapeutics (RNAZ) has entered into a definitive agreement to acquire Polynoma, a privately-held biotechnology immuno-oncology company. Polynoma is developing a late-stage candi...

6 months ago - Nasdaq

CK Life’s new CEO counts on Big Pharma experience to boost new drug success, earnings

Lance Yuen spent two decades at Bristol-Myers Squibb and Bayer in the region before becoming the CEO at CK Life Sciences last month.

1 year ago - South China Morning Post